uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update
Show others and affiliations
2014 (English)In: Clinical Pharmacology and Therapeutics, ISSN 0009-9236, E-ISSN 1532-6535, Vol. 96, no 4, 423-428 p.Article in journal (Refereed) Published
Abstract [en]

Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for simvastatin based on SLCO1B1 genotype. This article is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy.

Place, publisher, year, edition, pages
2014. Vol. 96, no 4, 423-428 p.
National Category
Pharmacology and Toxicology
URN: urn:nbn:se:uu:diva-236044DOI: 10.1038/clpt.2014.125ISI: 000342675400019OAI: oai:DiVA.org:uu-236044DiVA: diva2:764287
Swedish Research Council, 523-2008-5568, 521-2011-2440
Available from: 2014-11-18 Created: 2014-11-12 Last updated: 2016-02-19

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Wadelius, Mia
By organisation
Clinical pharmacogenomics and osteoporosisScience for Life Laboratory, SciLifeLab
In the same journal
Clinical Pharmacology and Therapeutics
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 168 hits
ReferencesLink to record
Permanent link

Direct link